Stannsoporfin

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameStannsoporfin
Drug Alias Name锡泊芬Torcanestansoporfinastannsoporfinestannsoporfinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeme oxygenase 1 inhibitorsHeme oxygenase 2 inhibitors
TargetsHeme oxygenase 2Heme oxygenase 1
Therapy Area/IndicationsHyperbilirubinemiaPorphyriasNutritional and Metabolic Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineVietnam +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesShire Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInfacare Pharmaceuticals Corporation, A Mallinckrodt CompanyEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentNational Center For Research Resources
Active IndicationsN/A
Inactive IndicationsHyperbilirubinemiaPorphyriasNutritional and Metabolic Diseases +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG